Evolus (EOLS) Earnings Date & Reports

Key Takeaways

• Evolus reported third-quarter 2026 global net revenue of $78 million, a 13% increase year over year and modestly above the consensus estimate of about $77.6 million.
• GAAP (Generally Accepted Accounting Principles) earnings came in at a loss of $0.19 per share, wider than the consensus estimate of roughly a $0.07 loss per share.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was positive for a fourth consecutive quarter, improving by $4 million versus the prior year.
• Management reaffirmed its full-year 2026 outlook and its 2028 long-term targets, including $450 million to $500 million in total net revenue.
• The company expects U.S. Food and Drug Administration (FDA) approval of Evolysse Sculpt by the end of 2026, a key portfolio catalyst.
• For more details on Evolus, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Discover new market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Evolus (NASDAQ: EOLS) is a global performance beauty company best known for Jeuveau, its injectable neurotoxin dedicated exclusively to aesthetics, alongside a growing portfolio of hyaluronic acid (HA) fillers and skin-quality products. This quarterly report matters because it tests whether Evolus can sustain double-digit revenue growth while steadily converting that growth into profitability. The third quarter was particularly important as the company continued commercializing its Evolysse and Estyme HA gel lines and awaited FDA action on Evolysse Sculpt. With adjusted EBITDA now positive for four straight quarters, investors are watching whether operating leverage is durable enough to support the company's ambitious multi-year targets.

Reported Results

Evolus delivered third-quarter 2026 global net revenue of $78 million, up 13% from the prior-year period and slightly ahead of the consensus estimate of approximately $77.6 million. Global toxin revenue reached $70.1 million, while injectable HA products contributed $7.9 million. Through the first nine months of 2026, total net revenue rose 14% year over year to $235.2 million.

On the bottom line, Evolus posted a GAAP net loss of $0.19 per share, wider than the consensus expectation of roughly a $0.07 loss per share. Reported gross margin was 65%, while adjusted gross margin, which excludes amortization of intangible assets, was 66.1%. Management highlighted a fourth consecutive quarter of positive adjusted EBITDA, with a $4 million year-over-year improvement, reflecting ongoing operating leverage.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to uncover new ideas across industries and refine your research process.

Market Reaction and Investor Sentiment

Evolus shares closed at $7.47 on the day of the report, with the stock ticking modestly higher in after-hours trading as investors weighed the revenue beat against the wider-than-expected GAAP loss. Sentiment around the name remains focused on two themes: the durability of double-digit revenue growth and the pace at which Evolus converts that growth into positive earnings. The fourth consecutive quarter of positive adjusted EBITDA was viewed constructively, reinforcing confidence in the company's expense discipline, even as the headline EPS miss reminded investors that GAAP profitability is still a work in progress.

Forward Outlook and Key Factors to Monitor

Evolus reaffirmed its full-year 2026 financial outlook, including an expectation that its Evolysse and Estyme injectable HA gels will contribute 10% to 12% of full-year total net revenue. The company also maintained its low- to mid-single-digit adjusted EBITDA margin target for 2026 and its 2028 long-term outlook of $450 million to $500 million in total net revenue, implying a three-year compound annual growth rate (CAGR) of 15% to 19%.

The most closely watched near-term catalyst is the anticipated FDA approval of Evolysse Sculpt by the end of 2026. Approval would expand the company's filler portfolio and, management has indicated, support progress toward its 2028 objectives. Investors should also monitor the timeline for an Evolysse lips submission, planned before year-end, with a potential launch in early 2028.

Beyond injectables, Evolus continues to develop a longer-term pipeline that includes Profhilo for skin quality, with U.S. approval anticipated around 2030, and an option to acquire a hair-growth asset. Gross margin trends, HA gel adoption, and the pace of operating expense growth will remain important signals of whether the company can sustain its path toward broader profitability without sacrificing commercial momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations